Wagner Bowman Management Corp trimmed its holdings in shares of Colgate-Palmolive (NYSE:CL) by 14.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 17,842 shares of the company’s stock after selling 3,099 shares during the period. Wagner Bowman Management Corp’s holdings in Colgate-Palmolive were worth $1,278,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in CL. Dimensional Fund Advisors LP lifted its holdings in Colgate-Palmolive by 3.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,737,377 shares of the company’s stock worth $103,412,000 after buying an additional 57,606 shares during the period. Geode Capital Management LLC lifted its stake in shares of Colgate-Palmolive by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 10,540,277 shares of the company’s stock valued at $626,200,000 after purchasing an additional 768,550 shares during the period. First Command Bank lifted its stake in shares of Colgate-Palmolive by 27.4% in the 1st quarter. First Command Bank now owns 1,948 shares of the company’s stock valued at $133,000 after purchasing an additional 419 shares during the period. Nwam LLC acquired a new position in shares of Colgate-Palmolive in the 1st quarter valued at about $211,000. Finally, Sippican Capital Advisors lifted its stake in shares of Colgate-Palmolive by 11.7% in the 1st quarter. Sippican Capital Advisors now owns 10,525 shares of the company’s stock valued at $721,000 after purchasing an additional 1,100 shares during the period. Hedge funds and other institutional investors own 75.64% of the company’s stock.
A number of brokerages have recently issued reports on CL. Deutsche Bank boosted their price objective on Colgate-Palmolive from $74.00 to $76.00 and gave the company a “hold” rating in a research note on Friday, July 12th. UBS Group boosted their price objective on Colgate-Palmolive from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Monday, July 29th. JPMorgan Chase & Co. raised Colgate-Palmolive from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $62.00 to $70.00 in a research note on Monday, April 29th. Argus boosted their target price on Colgate-Palmolive from $72.00 to $82.00 and gave the company a “buy” rating in a research report on Tuesday, June 11th. Finally, Bank of America set a $80.00 target price on Colgate-Palmolive and gave the company a “buy” rating in a research report on Friday, July 12th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and six have assigned a buy rating to the company. Colgate-Palmolive currently has an average rating of “Hold” and a consensus target price of $73.13.
Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings data on Friday, July 26th. The company reported $0.72 EPS for the quarter, hitting analysts’ consensus estimates of $0.72. The firm had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.88 billion. Colgate-Palmolive had a negative return on equity of 10,821.98% and a net margin of 14.77%. The company’s revenue for the quarter was down .5% on a year-over-year basis. During the same period in the previous year, the company posted $0.77 EPS. On average, equities research analysts predict that Colgate-Palmolive will post 2.84 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 15th. Shareholders of record on Thursday, July 18th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date was Wednesday, July 17th. Colgate-Palmolive’s dividend payout ratio is currently 57.91%.
In other Colgate-Palmolive news, SVP John J. Huston sold 473 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $72.93, for a total transaction of $34,495.89. Following the completion of the sale, the senior vice president now directly owns 59,668 shares of the company’s stock, valued at approximately $4,351,587.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ian M. Cook sold 19,500 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $74.19, for a total value of $1,446,705.00. Following the sale, the insider now directly owns 1,127,542 shares of the company’s stock, valued at $83,652,340.98. The disclosure for this sale can be found here. Insiders have sold a total of 544,785 shares of company stock valued at $39,141,695 over the last three months. Corporate insiders own 1.14% of the company’s stock.
Colgate-Palmolive Company Profile
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.